The report provides comprehensive information on the
Angiopoietin 2 (Ang 2 or ANGPT2), targeted therapeutics, complete with analysis
by indications, stage of development, mechanism of action (MoA), route of
administration (RoA) and molecule type. The report also covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases. Additionally, the
report provides an overview of key players involved in Angiopoietin 2 (Ang 2 or
ANGPT2) targeted therapeutics development and features dormant and discontinued
projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619223-angiopoietin-2-ang-2-or-angpt2-pipeline-review-h2-2016
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic
landscape for Angiopoietin 2 (Ang 2 or ANGPT2)
- The report reviews Angiopoietin 2 (Ang 2 or ANGPT2)
targeted therapeutics under development by companies and universities/research
institutes based on information derived from company and industry-specific
sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Angiopoietin 2
(Ang 2 or ANGPT2) targeted therapeutics and enlists all their major and minor
projects
- The report assesses Angiopoietin 2 (Ang 2 or ANGPT2)
targeted therapeutics based on mechanism of action (MoA), route of
administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued
pipeline projects
- The report reviews latest news and deals related to
Angiopoietin 2 (Ang 2 or ANGPT2) targeted therapeutics
Reasons to
buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and
indications for Angiopoietin 2 (Ang 2 or ANGPT2)
- Identify the use of drugs for target identification and
drug repurposing
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Angiopoietin 2 (Ang 2 or ANGPT2) development landscape
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
Table of
Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Angiopoietin 2 (Ang 2 or ANGPT2) Overview 7
Therapeutics Development 8
Angiopoietin 2 (Ang 2 or ANGPT2) - Products under
Development by Stage of Development 8
Angiopoietin 2 (Ang 2 or ANGPT2) - Products under
Development by Therapy Area 9
Angiopoietin 2 (Ang 2 or ANGPT2) - Products under
Development by Indication 10
Angiopoietin 2 (Ang 2 or ANGPT2) - Pipeline Products Glance
12
Late Stage Products 12
Early Stage Products 13
Angiopoietin 2 (Ang 2 or ANGPT2) - Products under
Development by Companies 14
Angiopoietin 2 (Ang 2 or ANGPT2) - Therapeutics Assessment
17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Angiopoietin 2 (Ang 2 or ANGPT2) - Companies Involved in
Therapeutics Development 23
Amgen Inc. 23
AnGes MG, Inc. 24
Boehringer Ingelheim GmbH 25
Eli Lilly and Company 26
F. Hoffmann-La Roche Ltd. 27
MedImmune, LLC 28
Regeneron Pharmaceuticals, Inc. 29
RXi Pharmaceuticals Corporation 30
Silence Therapeutics Plc 31
Synergys Biotherapeutics, Inc. 32
Angiopoietin 2 (Ang 2 or ANGPT2) - Drug Profiles 33
(aflibercept + nesvacumab) - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
AG-30/5C - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
Anti-Angiopoietin-1/2 Monoclonal Antibody - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Antisense RNAi Oligonucleotides to Inhibit Angiopoietin-2
for Retinal Disease and Oncology - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
AP-202 - Drug Profile 37
Access Report @ https://www.wiseguyreports.com/reports/619223-angiopoietin-2-ang-2-or-angpt2-pipeline-review-h2-2016
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
No comments:
Post a Comment